Global C-MET/HGF Inhibitors Competitive Landscape Professional Research Report 2024

Global C-MET/HGF Inhibitors Competitive Landscape Professional Research Report 2024



Research Summary

C-MET/HGF inhibitors are a class of targeted therapy drugs that specifically target the C-MET receptor and its ligand, hepatocyte growth factor (HGF). C-MET is a receptor tyrosine kinase that plays a crucial role in cell growth, survival, migration, and invasion, and its overactivation is often associated with cancer development and progression. HGF is the natural ligand that binds to C-MET and activates its signaling pathway. By inhibiting the interaction between C-MET and HGF, these inhibitors block the downstream signaling pathways that promote tumor growth and metastasis. C-MET/HGF inhibitors have shown promise as potential treatments for various types of cancer, including lung, gastric, and kidney cancers. They are typically used in combination with other therapies or as a targeted monotherapy in patients with tumors that express high levels of C-MET and are refractory to standard treatments. Clinical trials are ongoing to further evaluate the safety and efficacy of C-MET/HGF inhibitors in cancer treatment.

According to DIResearch's in-depth investigation and research, the global C-MET/HGF Inhibitors market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of C-MET/HGF Inhibitors include Exelixis, Ipsen, Pfizer, Novartis, Takeda, Merck KGaA, Merck, Daiichi Sankyo, GSK, Bristol-Myers Squibb(BMS), AVEO Pharmaceuticals, Roche, Amgen, AstraZeneca, Mirati Therapeutics, Eli Lilly, Johnson & Johnson, Eisai, Hutchison MediPharma, Kringle Pharmaceuticals etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of C-MET/HGF Inhibitors. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global C-MET/HGF Inhibitors market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the C-MET/HGF Inhibitors market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of C-MET/HGF Inhibitors industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of C-MET/HGF Inhibitors Include:

Exelixis

Ipsen

Pfizer

Novartis

Takeda

Merck KGaA

Merck

Daiichi Sankyo

GSK

Bristol-Myers Squibb(BMS)

AVEO Pharmaceuticals

Roche

Amgen

AstraZeneca

Mirati Therapeutics

Eli Lilly

Johnson & Johnson

Eisai

Hutchison MediPharma

Kringle Pharmaceuticals

C-MET/HGF Inhibitors Product Segment Include:

Cabozantinib

Crizotinib

Others

C-MET/HGF Inhibitors Product Application Include:

Hospital

Drug Store

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global C-MET/HGF Inhibitors Industry PESTEL Analysis

Chapter 3: Global C-MET/HGF Inhibitors Industry Porter’s Five Forces Analysis

Chapter 4: Global C-MET/HGF Inhibitors Major Regional Market Size and Forecast Analysis

Chapter 5: Global C-MET/HGF Inhibitors Market Size and Forecast by Type and Application Analysis

Chapter 6: North America C-MET/HGF Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe C-MET/HGF Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China C-MET/HGF Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) C-MET/HGF Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America C-MET/HGF Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa C-MET/HGF Inhibitors Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global C-MET/HGF Inhibitors Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources


1 C-MET/HGF Inhibitors Market Overview
1.1 Product Definition and Statistical Scope
1.2 C-MET/HGF Inhibitors Product by Type
1.2.1 Global C-MET/HGF Inhibitors Market Size by Type, 2023 VS 2024 VS 2030
1.2.2 Cabozantinib
1.2.3 Crizotinib
1.2.4 Others
1.3 C-MET/HGF Inhibitors Product by Application
1.3.1 Global C-MET/HGF Inhibitors Market Size by Application, 2023 VS 2024 VS 2030
1.3.2 Hospital
1.3.3 Drug Store
1.4 Global C-MET/HGF Inhibitors Market Revenue Analysis (2019-2030)
1.5 C-MET/HGF Inhibitors Market Development Status and Trends
1.5.1 C-MET/HGF Inhibitors Industry Development Status Analysis
1.5.2 C-MET/HGF Inhibitors Industry Development Trends Analysis
2 C-MET/HGF Inhibitors Market PESTEL Analysis
2.1 Political Factors Analysis
2.2 Economic Factors Analysis
2.3 Social Factors Analysis
2.4 Technological Factors Analysis
2.5 Environmental Factors Analysis
2.6 Legal Factors Analysis
3 C-MET/HGF Inhibitors Market Porter's Five Forces Analysis
3.1 Competitive Rivalry
3.2 Threat of New Entrants
3.3 Bargaining Power of Suppliers
3.4 Bargaining Power of Buyers
3.5 Threat of Substitutes
4 Global C-MET/HGF Inhibitors Market Analysis by Regions
4.1 C-MET/HGF Inhibitors Overall Market: 2023 VS 2024 VS 2030
4.2 Global C-MET/HGF Inhibitors Revenue and Forecast Analysis (2019-2030)
4.2.1 Global C-MET/HGF Inhibitors Revenue and Market Share by Region (2019-2024)
4.2.2 Global C-MET/HGF Inhibitors Revenue Forecast by Region (2025-2030)
5 Global C-MET/HGF Inhibitors Market Size by Type and Application
5.1 Global C-MET/HGF Inhibitors Market Size by Type
5.2 Global C-MET/HGF Inhibitors Market Size by Application
6 North America
6.1 North America C-MET/HGF Inhibitors Market Size and Growth Rate Analysis (2019-2030)
6.2 North America Key Manufacturers Analysis
6.3 North America C-MET/HGF Inhibitors Market Size by Type
6.4 North America C-MET/HGF Inhibitors Market Size by Application
6.5 North America C-MET/HGF Inhibitors Market Size by Country
6.5.1 US
6.5.2 Canada
7 Europe
7.1 Europe C-MET/HGF Inhibitors Market Size and Growth Rate Analysis (2019-2030)
7.2 Europe Key Manufacturers Analysis
7.3 Europe C-MET/HGF Inhibitors Market Size by Type
7.4 Europe C-MET/HGF Inhibitors Market Size by Application
7.5 Europe C-MET/HGF Inhibitors Market Size by Country
7.5.1 Germany
7.5.2 France
7.5.3 United Kingdom
7.5.4 Italy
7.5.5 Spain
7.5.6 Benelux
8 China
8.1 China C-MET/HGF Inhibitors Market Size and Growth Rate Analysis (2019-2030)
8.2 China Key Manufacturers Analysis
8.3 China C-MET/HGF Inhibitors Market Size by Type
8.4 China C-MET/HGF Inhibitors Market Size by Application
9 APAC (excl. China)
9.1 APAC (excl. China) C-MET/HGF Inhibitors Market Size and Growth Rate Analysis (2019-2030)
9.2 APAC (excl. China) Key Manufacturers Analysis
9.3 APAC (excl. China) C-MET/HGF Inhibitors Market Size by Type
9.4 APAC (excl. China) C-MET/HGF Inhibitors Market Size by Application
9.5 APAC (excl. China) C-MET/HGF Inhibitors Market Size by Country
9.5.1 Japan
9.5.2 South Korea
9.5.3 India
9.5.4 Australia
9.5.5 Indonesia
9.5.6 Vietnam
9.5.7 Malaysia
9.5.8 Thailand
10 Latin America
10.1 Latin America C-MET/HGF Inhibitors Market Size and Growth Rate Analysis (2019-2030)
10.2 Latin America Key Manufacturers Analysis
10.3 Latin America C-MET/HGF Inhibitors Market Size by Type
10.4 Latin America C-MET/HGF Inhibitors Market Size by Application
10.5 Latin America C-MET/HGF Inhibitors Market Size by Country
10.5.1 Mecixo
10.5.2 Brazil
11 Middle East & Africa
11.1 Middle East & Africa C-MET/HGF Inhibitors Market Size and Growth Rate Analysis (2019-2030)
11.2 Middle East & Africa Key Manufacturers Analysis
11.3 Middle East & Africa C-MET/HGF Inhibitors Market Size by Type
11.4 Middle East & Africa C-MET/HGF Inhibitors Market Size by Application
11.5 Middle East & Africa C-MET/HGF Inhibitors Market Size by Country
11.5.1 Saudi Arabia
11.5.2 South Africa
12 Market Competition by Manufacturers
12.1 Global C-MET/HGF Inhibitors Market Revenue by Key Manufacturers (2020-2024)
12.2 C-MET/HGF Inhibitors Competitive Landscape Analysis and Market Dynamic
12.2.1 C-MET/HGF Inhibitors Competitive Landscape Analysis
12.2.2 Global Key Manufacturers Headquarter and Key Area Sales
12.2.3 Market Dynamic
13 Key Companies Analysis
13.1 Exelixis
13.1.1 Exelixis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.1.2 Exelixis C-MET/HGF Inhibitors Product Portfolio
13.1.3 Exelixis C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.2 Ipsen
13.2.1 Ipsen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.2.2 Ipsen C-MET/HGF Inhibitors Product Portfolio
13.2.3 Ipsen C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.3 Pfizer
13.3.1 Pfizer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.3.2 Pfizer C-MET/HGF Inhibitors Product Portfolio
13.3.3 Pfizer C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.4 Novartis
13.4.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.4.2 Novartis C-MET/HGF Inhibitors Product Portfolio
13.4.3 Novartis C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.5 Takeda
13.5.1 Takeda Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.5.2 Takeda C-MET/HGF Inhibitors Product Portfolio
13.5.3 Takeda C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.6 Merck KGaA
13.6.1 Merck KGaA Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.6.2 Merck KGaA C-MET/HGF Inhibitors Product Portfolio
13.6.3 Merck KGaA C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.7 Merck
13.7.1 Merck Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.7.2 Merck C-MET/HGF Inhibitors Product Portfolio
13.7.3 Merck C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.8 Daiichi Sankyo
13.8.1 Daiichi Sankyo Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.8.2 Daiichi Sankyo C-MET/HGF Inhibitors Product Portfolio
13.8.3 Daiichi Sankyo C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.9 GSK
13.9.1 GSK Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.9.2 GSK C-MET/HGF Inhibitors Product Portfolio
13.9.3 GSK C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.10 Bristol-Myers Squibb(BMS)
13.10.1 Bristol-Myers Squibb(BMS) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.10.2 Bristol-Myers Squibb(BMS) C-MET/HGF Inhibitors Product Portfolio
13.10.3 Bristol-Myers Squibb(BMS) C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.11 AVEO Pharmaceuticals
13.11.1 AVEO Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.11.2 AVEO Pharmaceuticals C-MET/HGF Inhibitors Product Portfolio
13.11.3 AVEO Pharmaceuticals C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.12 Roche
13.12.1 Roche Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.12.2 Roche C-MET/HGF Inhibitors Product Portfolio
13.12.3 Roche C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.13 Amgen
13.13.1 Amgen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.13.2 Amgen C-MET/HGF Inhibitors Product Portfolio
13.13.3 Amgen C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.14 AstraZeneca
13.14.1 AstraZeneca Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.14.2 AstraZeneca C-MET/HGF Inhibitors Product Portfolio
13.14.3 AstraZeneca C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.15 Mirati Therapeutics
13.15.1 Mirati Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.15.2 Mirati Therapeutics C-MET/HGF Inhibitors Product Portfolio
13.15.3 Mirati Therapeutics C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.16 Eli Lilly
13.16.1 Eli Lilly Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.16.2 Eli Lilly C-MET/HGF Inhibitors Product Portfolio
13.16.3 Eli Lilly C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.17 Johnson & Johnson
13.17.1 Johnson & Johnson Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.17.2 Johnson & Johnson C-MET/HGF Inhibitors Product Portfolio
13.17.3 Johnson & Johnson C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.18 Eisai
13.18.1 Eisai Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.18.2 Eisai C-MET/HGF Inhibitors Product Portfolio
13.18.3 Eisai C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.19 Hutchison MediPharma
13.19.1 Hutchison MediPharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.19.2 Hutchison MediPharma C-MET/HGF Inhibitors Product Portfolio
13.19.3 Hutchison MediPharma C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.20 Kringle Pharmaceuticals
13.20.1 Kringle Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.20.2 Kringle Pharmaceuticals C-MET/HGF Inhibitors Product Portfolio
13.20.3 Kringle Pharmaceuticals C-MET/HGF Inhibitors Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
14 Industry Chain Analysis
14.1 C-MET/HGF Inhibitors Industry Chain Analysis
14.2 C-MET/HGF Inhibitors Industry Raw Material and Suppliers Analysis
14.2.1 Upstream Key Raw Material Supply Analysis
14.2.2 Raw Material Suppliers and Contact Information
14.3 C-MET/HGF Inhibitors Typical Downstream Customers
14.4 C-MET/HGF Inhibitors Sales Channel Analysis
15 Research Findings and Conclusion
16 Methodology and Data Source
16.1 Methodology/Research Approach
16.2 Research Scope
16.3 Benchmarks and Assumptions
16.4 Date Source
16.4.1 Primary Sources
16.4.2 Secondary Sources
16.5 Data Cross Validation
16.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings